Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Illumina Laboratory Services, |
RCV000315803 | SCV000448491 | likely benign | Carcinoma of pancreas | 2016-06-14 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000700928 | SCV000829705 | uncertain significance | Pancreatic adenocarcinoma | 2024-05-04 | criteria provided, single submitter | clinical testing | This sequence change replaces arginine, which is basic and polar, with cysteine, which is neutral and slightly polar, at codon 545 of the PALLD protein (p.Arg545Cys). This variant is present in population databases (rs548068667, gnomAD 0.01%). This variant has not been reported in the literature in individuals affected with PALLD-related conditions. ClinVar contains an entry for this variant (Variation ID: 348045). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV004021956 | SCV002606333 | uncertain significance | not specified | 2023-12-31 | criteria provided, single submitter | clinical testing | The p.R1032C variant (also known as c.3094C>T), located in coding exon 17 of the PALLD gene, results from a C to T substitution at nucleotide position 3094. The arginine at codon 1032 is replaced by cysteine, an amino acid with highly dissimilar properties. This amino acid position is conserved. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |